GSK-626616
GSK-626616 is a potent, orally bioavailable inhibitor of DYRK3 (IC50=0.7 nM) . GSK-626616 inhibits other members of the DYRK family (e.g., DYRK1A and DYRK2) with similar potency, which is a potential therapy for the treatment of anemia[1].
Product Specifications
CAS Number
[1025821-33-3]
UNSPSC
12352005
Hazard Statement
H302, H315, H319, H335
Target
DYRK
Type
Reference compound
Related Pathways
Protein Tyrosine Kinase/RTK
Applications
COVID-19-immunoregulation
Field of Research
Cardiovascular Disease
Assay Protocol
https://www.medchemexpress.com/gsk-626616.html
Purity
99.77
Solubility
DMSO : 50 mg/mL (ultrasonic)
Smiles
O=C1N=C(NC2=C(Cl)C=CC=C2Cl)S/C1=C\C3=CC=C4N=CC=NC4=C3
Molecular Formula
C18H10Cl2N4OS
Molecular Weight
401.27
Precautions
H302, H315, H319, H335
References & Citations
[1]Connie L. Erickson-Miller, et al. GSK626616: A DYRK3 Inhibitor as a Potential New Therapy for the Treatment of Anemia. Blood 2007 110:510; |[2]Wippich F, et al. Dual specificity kinase DYRK3 couples stress granule condensation/dissolution to mTORC1 signaling. Cell. 2013;152 (4) :791-805.
Shipping Conditions
Room Temperature
Storage Conditions
-20°C, 3 years; 4°C, 2 years (Powder)
Scientific Category
Reference compound1
Clinical Information
No Development Reported
Isoform
DYRK1; DYRK2; DYRK3
Available Sizes
Curated Selection
Explore Other Products
Discover premium biology products from our extensive collection of 20M+ items
